Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Other Working Capital Changes (2016 - 2025)

Aethlon Medical filings provide 15 years of Other Working Capital Changes readings, the most recent being $304795.0 for Q1 2025.

  • On a quarterly basis, Other Working Capital Changes rose 4.23% to $304795.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $190624.0, a 80.25% decrease, with the full-year FY2025 number at $4270.0, down 60.0% from a year prior.
  • Other Working Capital Changes hit $304795.0 in Q1 2025 for Aethlon Medical, up from $16566.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $521839.0 in Q1 2022 to a low of -$292071.0 in Q3 2024.
  • Median Other Working Capital Changes over the past 5 years was $23715.0 (2022), compared with a mean of $82675.3.
  • Biggest five-year swings in Other Working Capital Changes: surged 2809.02% in 2021 and later crashed 2078.53% in 2024.
  • Aethlon Medical's Other Working Capital Changes stood at $107767.0 in 2021, then tumbled by 77.99% to $23715.0 in 2022, then rose by 22.01% to $28934.0 in 2023, then plummeted by 42.75% to $16566.0 in 2024, then surged by 1739.88% to $304795.0 in 2025.
  • The last three reported values for Other Working Capital Changes were $304795.0 (Q1 2025), $16566.0 (Q4 2024), and -$292071.0 (Q3 2024) per Business Quant data.